Patients With Refractory Crohn’s Disease Successfully Treated With Ustekinumab

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

“…29 Although the dosing used in psoriasis is typically lower than doses used in CD, very few serious AEs to ustekinumab have been reported in RCTs and open-label cohorts of CD patients. [16][17][18][19] There are several limitations to our study. Primarily, this was a retrospective evaluation.…”

“…Few studies have described the open-label experience with ustekinumab in CD and currently published series are limited by small sample size, lack of objectively defined response, and short duration of follow-up. [16][17][18][19] Here, we aim to describe the real world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in a large multicentre cohort of CD patients failing anti-TNF therapy. Second, we assess predictors of response and the safety profile of ustekinumab.…”

Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

“…[8][9][10] Studies from clinical practice to date were performed before the drug came onto the market, when it was only indicated for psoriasis, was requested for compassionate use, and was administered subcutaneously (SC) and at various doses. [11][12][13][14][15] Khorrami et al 13 studied 116 patients treated with ustekinumab SC in several Spanish hospitals. While most patients (87%) had previously experienced failure with more than two anti-TNFα agents, very promising results were reported for clinical response in the short and long term, usefulness in perianal disease and safety.…”

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

“…Several retrospective cohort studies have reported that ustekinumab induces a short and intermediate‐term clinical response in patients with CD refractory to anti‐TNF therapy . Our group reported data in 122 patients with severe refractory CD included in a multicentre retrospective cohort who began subcutaneous (SC) ustekinumab .…”